Abstract Objective To investigate the therapeutic effects and toxic effects of radiochemotherapy versus chemotherapy alone in patients with advanced gastric cancer after gastrectomy. Methods A total of 183 patients with stage Ⅱ—Ⅳ(M0) gastric cancer, who received treatment after gastrectomy from 2004 to 2010, were included in the study. Of the 183 patients, 64 received radiochemotherapy after gastrectomy, and 119 received chemotherapy alone after gastrectomy. The survival rates and hematological and gastrointestinal toxic effects were compared between the two groups;survival difference was also analyzed after the patients were stratified by TNM stage, number of metastatic lymph nodes, and extent of lymph node dissection (D0, D1, and D2). The Kaplan-Meier method was used for calculating survival rates, and the log-rank test was used for survival difference analysis and univariate prognostic analysis;the chi-square test was used for comparing toxic effects between the two groups. Results The follow-up rate was 87.8%;72 patients were followed up for at least 3 years, and 29 patients for at least 5 years. The 1-, 3-, and 5-year survival rates for the radiochemotherapy group were 86%, 62%, and 55%, respectively, as compared with 77%, 53%, and 43% for the chemotherapy group (P=0.079). There were no significant differences in grade 3—4 hematological and gastrointestinal toxic effects between the two groups (P=0.363 and 0.617). The univariate analysis showed that radiochemotherapy had a significantly better survival benefit than chemotherapy alone in patients with stage ⅢB—Ⅳ(M0) gastric cancer, patients who underwent D0 lymph node dissection, and patients with more than 6 metastatic lymph nodes (P=0.022, 0.025, and 0.021). Conclusions Compared with chemotherapy alone, radiochemotherapy tends to improve survival in patients with gastric cancer after gastrectomy, and its toxic effects are tolerable. The patients with stage ⅢB—Ⅳ(M0) gastric cancer, patients who undergo D0 lymph node dissection, and patients with more than 6 metastatic lymph nodes can benefit from radiochemotherapy.
QIN Yu-e,ZHOU Fu-xiang,DAI Jing et al. Analysis of therapeutic effects of radiochemotherapy and chemotherapy alone in patients with advanced gastric cancer after gastrectomy[J]. Chinese Journal of Radiation Oncology, 2013, 22(4): 263-265.
QIN Yu-e,ZHOU Fu-xiang,DAI Jing et al. Analysis of therapeutic effects of radiochemotherapy and chemotherapy alone in patients with advanced gastric cancer after gastrectomy[J]. Chinese Journal of Radiation Oncology, 2013, 22(4): 263-265.
[1] 詹友庆,李威,孙晓卫,等.胃癌外科治疗的远期疗效研究.中华外科杂志,2005,43:1009. [2] Landry J, Tepper JE, Wood WC, et al. Patterns of failure following curative resection of gastric cancer. Int J Radiat Oncol Biol Phys,1990,191:1357-1362. [3] Gunderson LL, Sosin H. Adenocarcinoma of the stomach:areas of failure in a reoperation series (second or symptomatic look):clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys,1982,8:1-11. [4] McNeer G, VandenBerg HJ, Donn FY, et al. A critical evaluation of subtotal gastrectomy for the cure of cancer of the stomach. Ann Surg,1951,134:2-7. [5] Thomson FB, Robins RE. Local recurrence following subtotal resection for gastric carcinoma. Surg Gynecol Obstet,1952,95:341-344. [6] Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med,2001,345:725-730. [7] Bora H, Unsal D, Akmansu M, et al. Results of chemoirradiation after curative resection of locally advanced gastric cancer. Int J Clin Pract,2004,58:451-456. [8] Hundahl SA, M acdonald JS, Benedetti J, et al. Surgical treatment variation in a prospective, randomized trial of chemo radiotherapy in gastric cancer. The effect of undertredtment. Ann Surg Oncol,2002,9:278-286. [9] Kim S, Lim DH, Lee J, et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys,2005,63:1279-1285. [10] Lee J, Lim do H, Kim S, et al. Phase Ⅲ trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection:the ARTIST trial. J Clin Oncol,2012,30:268-273.
2013, Vol. 22 
